Saturday 17 October 2026
Export PTHS’s income statement to Excel — free account
Pelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.1%, free cash flow fell 1,615.0% and total debt rose 2,692.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.15
0.11
−0.54%
Follow PTHS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 4.50 | 6.30 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 60.00 | 54.29 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 4 | 11 | 92 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.18 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 17 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | 76.25 | |||||
| EBT | — | — | — | — | — | (1) | (2) | (7) | (8) | (51) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (301.91) | |||||
| Net income | — | — | — | — | — | (1) | (2) | (7) | (8) | (43) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 1 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 8.93 | ||||
| Earnings | — | — | — | — | — | — | (56.52) | (57.80) | (14.30) | (23.04) | |||||
| Cash flow | — | — | — | — | — | 0.00 | (36.03) | (7.68) | (10.39) | (12.01) | |||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.05) | |||||
| Free cash flow | — | — | — | — | — | 0.00 | (36.03) | (7.68) | (10.39) | (12.07) | |||||
| Book value | — | — | — | — | — | 0.00 | (85.21) | (50.47) | (4.87) | 20.68 | |||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 1.50 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (3.28) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (2) | (2) | (1) | (6) | (23) | ||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | |||||
| Free cash flow | — | — | — | — | — | (2) | (2) | (1) | (6) | (23) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | (3) | (4) | (6) | (3) | 27 | ||||
| Total debt | — | — | — | — | — | — | 1 | 1 | 2 | 31 | |||||
| Net debt | — | — | — | — | — | — | 0 | 1 | 2 | 13 | |||||
| Shareholders’ equity | — | — | — | — | — | (4) | (4) | (6) | (3) | 39 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (8,924.14) | (9,743.63) | (1,085.71) | (65.75) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (38.76) | |||||
| ROE | — | — | — | — | — | 0.00 | 66.57 | 145.42 | 173.72 | (239.55) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Pelthos Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NMRA Neumora Therapeutics, Inc. | $80.2M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLLS Cellectis S.A. | $79.9M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| PMN Promis Neurosciences | $78.0M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $77.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | |
| TELO Telomir Pharmaceuticals, Inc. | $77.3M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| NTRB Nutriband Inc. | $76.2M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| CRDF Cardiff Oncology, Inc. | $75.5M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| ACRV Acrivon Therapeutics, Inc. | $75.4M | — (loss-making) | — | — | n/m | +12.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OKYO OKYO Pharma Limited Sponsored ADR | $75.1M | — (loss-making) | — | — | n/m | +37.39% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $76.8M | — | — | −21.89% | — | −12.18% | 0.00% | 0.00% |
Pelthos Therapeutics Inc. (PTHS) key facts
- Pelthos Therapeutics Inc. (PTHS) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, PTHS traded at $20.15, a market capitalization of $77.6 million.
- Return on equity was −239.6% and debt-to-equity -46.58.
- Its Altman Z-score is −0.75 (distress zone) for fiscal 2025.
Pelthos Therapeutics Inc. (PTHS) Latest News
No news at this impact. Lower the threshold for more.